Patent Pool Strikes Deals with Cipla, Pfizer For New HIV, TB Drugs
Executive Summary
The Medicines Patent Pool, a UN-backed public health organization, has announced deals with two major global pharma firms aimed at providing innovative, effective and affordable treatment for people - including children - living with HIV and TB.
You may also be interested in...
Pharma, Non-Profits Ally To Advance TB Drug Combinations
The Project to Accelerate New Treatments for Tuberculosis (PAN-TB) is pulling together philanthropic, non-profit and private sector participants to collaboratively run Phase II trials for five drugs from Janssen, Otsuka, the TB Alliance and the Bill & Melinda Gates Medical Research Institute.
Pfizer Licenses TB Drug Sutezolid To Medicines Patent Pool
Pfizer and the Medicines Patent Pool have signed a licensing agreement for the US firm’s investigational TB compound, sutezolid. The move should help to speed up the availability of the product, whose development appears to have been stalled since 2013.
New Patent Pool Deal For TB Drug Abandoned By Pfizer Could Spark Development
A new licensing deal between the Medicines Patent Pool and a leading academic center for a Phase II tuberculosis drug candidate originally in development by Pfizer could signal a real opportunity for getting a commercially challenging product to market. Public health groups, while welcoming the move, have noted that the deal is no guarantee that the medicine will actually reach the patients who need it, though.